Takeda's Takhzyro Approved by FDA for Pediatric Expansion and Generates JPY 223.9 Billion in Revenue
Approved Drug and Mechanism of Action
Takeda Pharmaceutical Company Limited (NYSE: TAK, TSE: 4502)'s Takhzyro (lanadelumab-flyo) is a fully human IgG1 monoclonal antibody that selectively inhibits active plasma kallikrein. It reduces bradykinin production to prevent attacks of hereditary angioedema (HAE) and is currently a marketed drug, not a clinical candidate. It provides a preventive option with subcutaneous administration every 2 or 4 weeks for a rare disease affecting approximately 1 in 50,000 people, which can be life-threatening when involving the larynx.
Clinical Evidence
The FDA approval was based on the randomized, double-blind, placebo-controlled Phase 3 HELP trial, which evaluated 125 HAE patients aged 12 years and older over 26 weeks. The 300mg every 2 weeks dosing group reduced the monthly moderate-to-severe attack rate by 83% compared to placebo, with an adjusted p-value of less than 0.001. Eighty-nine percent of patients experienced a 70% or greater reduction in total attack rates, and 44% had no attacks at all over 26 weeks, numerically supporting the preventive efficacy that justifies the repeated dosing burden.
Regulatory History
The FDA applied Priority Review, Breakthrough Therapy designation, and Orphan Drug designation to BLA 761090 and approved it on August 23, 2018, for patients aged 12 years and older without an AdComm vote. On February 3, 2023, the label was expanded to include patients aged 2 years and older based on Phase 3 SPRING data. The European Union granted approval on November 22, 2018, following accelerated assessment and a positive opinion from the CHMP on October 18, 2018. Japan's Ministry of Health, Labour and Welfare approved it on March 28, 2022, for the prevention of HAE attacks in patients aged 12 years and older.
Market Performance and Competitive Landscape
The global HAE treatment market was valued at USD 3.6 billion in 2025, with the U.S. market at USD 1.287 billion. Takeda's FY2025 revenue from Takhzyro was JPY 223.9 billion, a 0.4% decrease year-over-year on a fixed exchange rate basis. Approximately 6,700 patients are being treated globally, providing a solid commercial foundation. However, BioCryst Pharmaceuticals (BCRX)'s oral kallikrein inhibitor Orladeyo (berotralstat), CSL Limited (CSL.AX)'s C1 esterase inhibitor Haegarda, and Ionis Pharmaceuticals (IONS)'s antisense therapy targeting prekallikrein, Dawnzera (donidalorsen), are segmenting the preventive market. Particularly, the FDA approved Dawnzera for administration every 4 or 8 weeks and Orladeyo for once-daily oral convenience on August 21, 2025, which are structurally pressuring Takhzyro's growth rate and patient retention.
Takhzyro is a marketed product that reduced moderate-to-severe attack rates by 83% in Phase 3 trials and generated JPY 223.9 billion in FY2025 revenue, accounting for approximately 5% of Takeda's total revenue, making it a key cash generator for its rare disease business. In the short term, the FDA-approved indication for patients aged 2 years and older and the treatment base of around 6,700 patients provide defensive strength in the USD 3.6 billion HAE market. In the medium to long term, the oral Orladeyo and the 4-week or 8-week dosing Dawnzera are competing for new patients and prescription switches by emphasizing dosing convenience. From a research and development and business development perspective, the efficacy across plasma kallikrein, prekallikrein, and C1 inhibition pathways, as well as dosing frequency, pediatric labeling, and real-world persistence, will determine asset value and market share.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=BLA761090